SPT Labtech and Semarion Partner to Automate Cell-Based Drug Screening Workflows
核心洞察
SPT Labtech (搜索) and Semarion (搜索) announced a strategic collaboration to integrate firefly (搜索) liquid handling platform with SemaCyte (搜索) microcarrier technology for automated cell assay development.
The partnership aims to overcome long-standing challenges in miniaturizing and automating complex cell biology processes through flexible, scalable workflows.
The collaboration will develop joint application protocols and workflow optimization strategies to provide researchers with more adaptable tools for cell-based discovery.
SPT Labtech (搜索), a global leader in innovative laboratory automation, has announced a strategic collaboration with Semarion (搜索), a University of Cambridge spin-out company from the Cavendish Laboratory. The partnership combines SPT Labtech's firefly (搜索) liquid handling platform with Semarion's SemaCyte (搜索) microcarrier technology to develop automated workflows that address unmet drug screening needs.
Technology Integration Addresses Automation Challenges
The collaboration integrates SPT Labtech (搜索)'s versatile firefly (搜索) liquid handling platform with Semarion (搜索)'s microcarrier-based approach to overcome long-standing challenges in miniaturizing and automating complex cell biology processes. The partnership aims to develop a flexible, scalable, and automated workflow that simplifies and accelerates key stages of adherent cell assay development.
According to the companies, this integration will set a new standard for flexibility and scalability in cell-based assay design, enabling researchers to more easily adapt workflows to their unique applications while improving efficiency and reproducibility. The platform will particularly benefit high-content image-based assays such as cell painting.
Industry Leaders Highlight Innovation Potential
Maryia Karpiyevich, Product Development Scientist at SPT Labtech (搜索), emphasized the collaboration's potential: "This collaboration is an exciting opportunity to explore how cutting-edge technologies like Semarion (搜索)'s microcarriers can be seamlessly integrated into flexible automation platforms like firefly (搜索). We're looking forward to developing tools that truly empower scientists working at the forefront of cellular research."
Jeroen Verheyen, CEO and Co-Founder at Semarion (搜索), highlighted the impact of combining technologies: "This partnership demonstrates the impact of combining our innovative microcarrier technology with agile automation. By integrating our SemaCyte (搜索) platform with SPT Labtech (搜索)'s firefly (搜索) system, we're unlocking a new class of flexible, miniaturized workflows that streamline assay development and unlock more scalable discovery pipelines."
Strategic Focus on Researcher Adaptability
Morten Frost, Chief Commercial Officer at SPT Labtech (搜索), outlined the company's commitment to supporting emerging technologies: "We are committed to supporting emerging technologies that align with our mission to make life in the lab easier. This partnership reflects our dedication to innovation that meets researchers where they are—scaling up, scaling down, and adapting as science evolves."
Development Roadmap and Applications
The collaboration will explore the development of joint application protocols, proof-of-concept data, and workflow optimization strategies. The goal is to provide researchers with more adaptable tools for cell-based discovery, addressing the evolving needs of pharmaceutical research and development.
Semarion (搜索) brings materials engineering and cell biology expertise from the University of Cambridge's Cavendish Laboratory, specifically targeting unmet drug screening needs through its microcarrier technology approach. The partnership represents a convergence of automation expertise and innovative cell culture solutions designed to enhance drug discovery workflows.